贝伐珠单抗在表皮生长因子受体敏感突变晚期非小细胞肺癌中的应用效果

Application effect of Bevacizumab in the treatment of non-small cell lung cancer with epidermal growth factor receptor-sensitive mutations

目的分析贝伐珠单抗治疗表皮生长因子受体(EGFR)敏感突变晚期非小细胞肺癌(NSCLC)的应用价值。方法选取2021年10月至2023年7月来源于桂林医学院附属医院的91例EGFR敏感突变晚期NSCLC患者,按随机数字表法将其分为参照组和研究组,参照组(n=45)实施阿美替尼治疗,研究组(n=46)开展阿美替尼结合贝伐珠单抗治疗。比较两组临床疗效、血清癌胚抗原(CEA)、细胞角蛋白19片段抗原21-1(CYFRA21-1)、糖类抗原153(CA153)、血清免疫球蛋白A(IgA)、免疫球蛋白M(IgM)、免疫球蛋白G(IgG)指标。结果研究组客观缓解率高于参照组,差异有统计学意义(P<0.05)。研究组治疗后CEA、CYFRA21-1、CA153指标低于参照组,两组治疗后CEA、CYFRA21-1、CA153指标均低于本组治疗前,差异有统计学意义(P<0.05)。研究组治疗后IgA、IgM、IgG指标高于参照组,两组治疗后IgA、IgM、IgG指标低于本组治疗前,差异有统计学意义(P<0.05)。结论阿美替尼结合贝伐珠单抗治疗EGFR敏感突变晚期NSCLC效果显著,能够有效提高临床治疗效率,控制肿瘤生长,提高机体免疫功能,因此值得临床应用及推广。

Objective To analyze the application value of Bevacizumab for the treatment of advanced non-small cell lung cancer(NSCLC)with epidermal growth factor receptor(EGFR)-sensitive mutations.Methods Ninety-one patients with advanced NSCLC with EGFR-sensitive mutations originating from Affiliated Hospital of Guilin Medical College from October 2021 to July 2023 were selected and divided into reference group and study group according to the randomized numerical table method,the reference group(n=45)implemented treatment with Alectinib,and the study group(n=46)carried out treatment with Alectinib combined with Bevacizumab.The clinical efficacy,serum carcinoembryonic antigen(CEA),cytokeratin 19 fragment antigen 21-1(CYFRA21-1),glycoconjugate antigen 153(CA153),serum immunoglobulin A(IgA),immunoglobulin M(IgM),and immunoglobulin G(IgG)indexes of the two groups were compared.Results The objective remission rate of the study group was higher than that of the reference group,and the difference was statistically significant(P<0.05).The indexes of CEA,CYFRA21-1 and CA153 in the study group after treatment were lower than those in the reference group,and the indexes of CEA,CYFRA21-1 and CA153 in the two groups after treatment were lower than those before treatment,with statistical significances(P<0.05).The IgA,IgM and IgG indexes of the study group after treatment were higher than those of the reference group,and the IgA,IgM and IgG indexes of the two groups after treatment were lower than those before treatment,with statistical significances(P<0.05).Conclusion The effect of Alectinib combined with Bevacizumab in the treatment of advanced NSCLC with EGFR-sensitive mutations is remarkable,which can effectively improve the clinical treatment efficiency,control the tumor growth,and improve the immune function of the body,so it is worthwhile to be clinically applied and promoted.